News Boehringer transfers schizophrenia DTx selling rights to Cli... Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
Digital Is DTx finally reaching drug-like efficacy? A Q&A with David... Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.
Digital Molecules, DTx, and a breakthrough in chronic cough Early evidence for a cough treatment digital therapeutic is compelling.
Digital Transforming Pharma: Insights from Frontiers Health 2025 pharmaphorum caught up with Emre Ozcan (Merck Group) after his onstage session at Frontiers Health.
Digital Ten years of innovation at Frontiers Health – Live from Berl... Tune into a wrap-up podcast from Frontiers Health 2025, with Jonah Comstock, Nicole Raleigh, and Jessica DaMassa.
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.